Industry expert's medical equipment report, “Global Coronary Stents Equipment Pipeline Analysis, Opportunity Assessment and Industry Projections to 2016” provides key data, information and analysis on the global coronary stents industry, a key sector within cardiovascular devices. The report provides industry landscape, competitive landscape and industry trends information the coronary stents industry . The report provides comprehensive data on the major industry developments affecting the industry, and key analytical content on the industry dynamics. The report also reviews the competitive landscape, key new product development and technology offerings.

Scope of the Research

- Key geographies covered include the US (United States), Canada, the UK (United Kingdom), Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Key sectors covered include Bare Metal Stents (BMS) and Drug Eluting Stents (DES).
- Annualized industry revenues data from 2002 to 2009, projection forward for 7 years to 2016. Firms shares data for 2008.
- Qualitative analysis of key industry trends, industry drivers, and restraints by each category within the coronary stents industry .
- The report also covers data on the leading industry players, the competitive landscape, and the leading new product development and technologies.
- Key Companies covered include Cordis, Boston Scientific Corporation, Medtronic and Abbott.

Why Should You Get This Report?

- Develop business strategies by understanding the trends and developments that are driving the coronary stents industry globally.
- Design and develop your product development, industry ing and sales strategies.
- Exploit Merger and Acquisition opportunities by identifying industry players with the most innovative pipeline.
- Develop successful market-entry strategies .
- Identify key players best positioned to take advantage of the emerging industry opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- What’s the next being thing in the coronary stents industry landscape? – Identify, understand and decide.
- Make more informed business decisions from the insightful and in-depth analysis of the global coronary stents industry and the factors shaping it.

Table Of Contents

1 Table of contents 3
I. 1 List of Data tables 6
I. 2 List of Charts 8

II Introduction: Coronary Stents 9
II. 1 GlobalData Report Guidance 9
3 Disease Data : Coronary Heart Disease (CHD) 10
III. 1 Pathophysiology 10
III. 2 Signs and Symptoms 10
III. 3 Risk Factor 11
III. 3.1 Major Risk Factors that can’t be Altered 11
III. 3.2 Major Risk Factors that can be Altered 11
III. 3.3 Other Risk Factors 11
III. 4 Diagnosis 12
III. 4.1 Electrocardiogram (ECG or EKG): 12
III. 4.2 Exercise thallium test: 12
III. 4.3 Echocardiography: 12
III. 4.4 Coronary angiography: 12
III. 4.5 Positron Emission Tomography (PET scanning): 12
III. 5 Treatment 12
III. 5.1 Coronary Heart Disease Epidemiology 12
III. 5.2 Treatment modalities for CHD 15
4 World Coronary Stents March ket Characterization 16
IV. 1 World Coronary Stents March ket, Sales s ($bn), Historical data, 2002 - 2009 16
IV. 2 World Coronary Stents March ket, Sales s ($bn), Forecasted data, 2009 - 2016 17
IV. 3 World Coronary Stents, March ket Dynamics 18
IV. 3.1 Coronary Stents: March ket Drivers 18
IV. 3.2 Coronary Stents: March ket Restraints 20
5 World Coronary Stents March ket: Segment Analysis 22
V. 1 Bare Metal Stents, Global, Sales ($bn), Historical data, 2002- 2009 22
V. 1.1 Bare Metal Stents, Global, Sales ($bn), Forecasted data, 2009- 2016 23
V. 2 World Bare Metal Stents: March ket Dynamics 24
V. 2.1 Bare Metal Stents: March ket Drivers 24
V. 2.2 Bare Metal Stents: March ket Restraints 24
V. 2.3 Drug Eluting Stents, Global, Sales ($bn), Historical data, 2002- 2009 25
V. 2.4 Drug Eluting Stents, Global, Sales ($bn), Forecasted data, 2009- 2016. 26
V. 3 World Drug Eluting Stents:March ket Dynamics 26
V. 3.1 Drug Eluting Stents: March ket Drivers 26
V. 3.2 Drug Eluting Stents: March ket Restraints 27

VI The World Coronary Stents March ket: Cross Country Analysis and Forecasted data s 28
VI. 1 Sales and Sales Forecasted data, By Country 29
VI. 1.1 US Coronary Stents industry, Sales ($ m), Historical data, from 2002 to 2009 29
VI. 1.2 US Coronary Stents industry, Sales ($ m), Forecasted data, from 2009 to 2016 30
VI. 1.3 Canada Coronary Stents industry, Sales ($ m), Historical data, from 2002 to 2009 31
VI. 1.4 Canada, Coronary Stents industry, Sales ($ m), Forecasted data, from 2002 to 2009 32
VI. 1.5 UK Coronary Stents industry, Sales ($ m), Historical data, from 2002 to 2009 33
VI. 1.6 UK Coronary Stents industry, Sales ($ m), Forecasted data, from 2009 to 2016 34
VI. 1.7 Italy, Coronary Stents industry, Sales ($ m), Historical data, from 2002 to 2009 35
VI. 1.8 Germany, Coronary Stents industry, Sales ($ m), Historical data, from 2002 to 2009 37
VI. 1.9 Germany, Coronary Stents industry, Sales ($ m), Forecasted data, from 2009 to 2016 38
VI. 1.10 France, Coronary Stents industry, Sales ($ m), Historical data, from 2002 to 2009 39
VI. 1.11 France, Coronary Stents industry, Sales ($ m), Forecasted data, from 2009 to 2016 40
VI. 1.12 Spain, Coronary Stents industry, Sales ($ m), Historical data, from 2002 to 2009 41
VI. 1.13 Spain, Coronary Stents industry, Sales ($ m), Forecasted data, from 2009 to 2016 42
VI. 1.14 Japan, Coronary Stents industry, Sales ($ m), Historical data, from 2002 to 2009 43
VI. 1.15 Japan, Coronary Stents industry, Sales ($ m), Forecasted data, from 2009 to 2016 44
VI. 1.16 China, Coronary Stents industry, Sales ($ m), Historical data, from 2002 to 2009 45
VI. 1.17 China, Coronary Stents industry, Sales ($ m), Forecasted data, from 2009 to 2016 46
VI. 1.18 India, Coronary Stents industry, Sales ($ m), Historical data, from 2002 to 2009 47
VI. 1.19 India, Coronary Stents industry, Sales ($ m), Forecasted data, from 2009 to 2016 48
VI. 1.20 Brazil, Coronary Stents industry, Sales ($ m), Historical data, from 2002 to 2009 49
VI. 1.21 Brazil, Coronary Stents industry, Sales ($ m), Forecasted data, from 2009 to 2016 50
VI. 1.22 Australia, Coronary Stents industry, Sales ($ m), Historical data, from 2002 to 2009 51
VI. 1.23 Australia, Coronary Stents industry, Sales ($ m), Forecasted data, from 2009 to 2016 52
7 World Coronary Stents March ket: Strategic Competitive Assesment 53
VII. 1 Boston Scientific Corporation 55
VII. 1.1 Overview: 55
VII. 2 Cordis Corporation 56
VII. 2.1 Overview 56
VII. 3 Abbott Laboratories 57
VII. 3.1 Overview 57
VII. 4 Medtronic, Inc. 58
VII. 4.1 Overview 58
8 World coronary Stents March ket, Key March keted products 60
VIII. 1 Key Coronary Stents in the March ket 60
VIII. 1.1 CYPHER sirolimus-eluting coronary stents (JNJ Cordis) 60
VIII. 1.2 PROMUS (Boston Scientific) 63
VIII. 1.3 ENDEAVOR (Medtronic) 66
VIII. 1.4 TAXUS Express2 (Boston Scientific) 69
VIII. 1.5 TAXUS Liberte (Boston Scientific) 71
VIII. 1.6 TriMaxx Coronary Stent (Abbott) 73
VIII. 1.7 MULTI-LINK FRONTIER Coronary Bifurcation Stent System (Abbott) 73
9 World Coronary Stents March ket: Strategic Pipeline Assessment 74
IX. 1 Pipeline Technology Assessment 74
IX. 1.1 Pipeline Technology Assessment for Coronary Stents by Development Stage, World 74
IX. 1.2 Emerging Technologies in the Coronary Stent March ket 77
IX. 2 Profiles of Promising Products Under Clinical Development: 78
IX. 2.1 BioMatrix Drug Eluting Stent (Biosensors) 78
IX. 2.2 NEVO Sirolimus-eluting Coronary Stent (Cordis) 80
IX. 2.3 PROTEX Coronary Stent System (Nexeon MedSystems) 83
IX. 2.4 Valecor Platinum Coronary Stent System (CorNovember a) 83
IX. 2.5 GTX Coronary Stent System (Cook Medical) 84
IX. 2.6 JST Drug-Eluting Stent (Japan Stent Technology) 85
IX. 2.7 ProGenic Pimecrolimus-eluting Coronary Stent System (BIOTRONIK SE and Co. KG) 85
IX. 2.8 MAHOROBA (KANEKA CORPORATION) 86
IX. 2.9 ProLink LP (Vascular Concepts Limited) 87
IX. 2.10 ChromoFlex Coronary Stent (DISA Vascular) 88
IX. 2.11 Next generation everolimus-based stent (Boston Scientific) 89
IX. 2.12 ProNovember a Sirolimus Eluting Stent (Vascular Concepts Limited) 89
IX. 2.13 Coroflex DEBlue (B. Braun Melsungen AG) 90
IX. 2.14 Endeavor Resolute (Medtronic) 92
IX. 2.15 XIENCE NANO (Abbott Vascular) 94
IX. 2.16 TAXUS Petal Bifurcation Paclitaxel-Eluting Stent System (Boston Scientific) 94
IX. 2.17 CYPHER Max (4.0) (RX) (Cordis Corporation) 97
IX. 3 Coronary Stents:List of Pipeline Products 97

X Global Coronary Stents March ket: Key Firms with Products in Clinical Development 104
X. 1.1 Biosensors International Group, Ltd. 104
X. 1.2 Cook Medical Incorporated 104
X. 1.3 OrbusNeich 105
X. 1.4 Vascular Concepts Limited 106
X. 1.5 CorNovember a, Inc. 106
X. 1.6 Nexeon MedSystems, Inc. 107

XI Global Coronary Stents March ket: Strategic Deals Analysis 108
XI. 1 Key Acquisitions 108
XI. 1.1 Medtronic Completes Acquisition Of Invatec And Affiliated Firms 109
XI. 1.2 Boston Scientific Takes Over Labcoat 109
XI. 1.3 Bayer MaterialScience Completes Acquisition Of PolyBioMed From Lombard Medical Technologies 109

XII Appendix 111
XII. 1 Definitions 111
XII. 1.1 Coronary Stents 111
XII. 2 Acronyms 111
XII. 3 Research Methodology 112
XII. 4 Secondary Research 113
XII. 5 Primary Research 113
XII. 6 Models 114
XII. 7 Forecasted data s 114
XII. 8 Expert Panels 114
XII. 9 GlobalData Consulting 115
XII. 10 Contact Us 115
XII. 11 Disclaimer 115

1.1 List of Data tables
Data table 1: Coronary Stents March ket, Global, Sales ($bn), 2002 - 2009 16
Data table 2: Coronary Stents March ket, Global, Sales ($bn), 2009 - 2016 17
Data table 3: Bare Metal Stents, Global, Sales ($bn), 2002- 2009 22
Data table 4: Bare Metal Stents, Global, Sales ($bn), 2009-2016 23
Data table 5: Drug Eluting Stents March ket, Global, Sales ($bn), 2002- 2009 25
Data table 6: Drug Eluting Stents, Global, Sales ($bn), 2009- 2016 26
Data table 7: Coronary Stents March ket, Cross Country Analysis, Sales (USD Million) and CAGR (%), from 2002 to 2016 28
Data table 8: Coronary Stents March ket, US, Sales ($ m), from 2002 to 2009 29
Data table 9: Coronary Stents March ket, US, Sales ($ m), from 2009 to 2016 30
Data table 10:Coronary Stents March ket, Canada, Sales ($ m), from 2002 to 2009 31
Data table 11:Coronary Stents March ket, Canada, Sales ($ m), from 2009 to 2016 32
Data table 12: Coronary Stents March ket, UK, Sales ($ m), from 2002 to 2009 33
Data table 13: Coronary Stents March ket, UK, Sales ($ m), from 2009 to 2016 34
Data table 14: Coronary Stents March ket, Italy, Sales ($ m), from 2002 to 2009 35
Data table 15: Coronary Stents March ket, Italy, Sales ($ m), from 2009 to 2016 36
Data table 16: Coronary Stents March ket, Germany, Sales ($ m), from 2002 to 2009 37
Data table 17: Coronary Stents March ket, Germany, Sales ($ m), from 2009 to 2016 38
Data table 18: Coronary Stents March ket, France, Sales ($ m), from 2002 to 2009 39
Data table 19: Coronary Stents March ket, France, Sales ($ m), from 2009 to 2016 40
Data table 20: Coronary Stents March ket, Spain, Sales ($ m), from 2002 to 2009 41
Data table 21: Coronary Stents March ket, Spain, Sales ($ m), from 2009 to 2016 42
Data table 22: Coronary Stents March ket, Japan, Sales ($ m), from 2002 to 2009 43
Data table 23: Coronary Stents March ket, Japan, Sales ($ m), from 2009 to 2016 44
Data table 24: Coronary Stents March ket,China, Sales ($ m), from 2002 to 2009 45
Data table 25: Coronary Stents March ket,China, Sales ($ m), from 2009 to 2016 46
Data table 26: Coronary Stents March ket, India, Sales ($ m), from 2002 to 2009 47
Data table 27: Coronary Stents March ket, India, Sales ($ m), from 2009 to 2016 48
Data table 28: Coronary Stents March ket, Brazil, Sales ($ m), from 2002 to 2009 49
Data table 29: Coronary Stents March ket, Brazil, Sales ($ m), from 2009 to 2016 50
Data table 30: Coronary Stents March ket, Australia, Sales ($ m), from 2002 to 2009 51
Data table 31: Coronary Stents March ket, Australia, Sales ($ m), from 2009 to 2016 52
Data table 32: Drug Eluting Stents March ket, Global, Market Shares s Sales (USD Million), 2009 53
Data table 33: Bare Metal Stents March ket, Global, Market Shares s Sales (USD Million), 2009 54
Data table 34: Boston Scientific Corporation, Coronary Stents, Pipeline Products 56
Data table 35: Cordis, Coronary Stents, Pipeline Products 57
Data table 36: Abbott Coronary Stents Pipeline Products 58
Data table 37: Medtronic Coronary Stents Pipeline Products 59
Data table 38: Current Drug-Eluting Stents Approved for Use in the US 60
Data table 39: CYPHER Coronary Stent 60
Data table 40: CYPHER (SIRIUS Pivotal Trial) 61
Data table 41: CYPHER (RAVEL Supporting Trial) 62
Data table 42: PROMUS Coronary Stent 63
Data table 43: PROMUS (SPIRIT III Trial)) 64
Data table 44: ENDEAVOR Coronary Stent 66
Data table 45: ENDEAVOR (ENDEAVOR III Trial)) 66
Data table 46: ENDEAVOR (ENDEAVOR IV Trial)) 68
Data table 47: TAXUS Express2 (TAXUS IV Trial)) 70
Data table 48: TAXUS Liberte (ATLAS Trial)) 72
Data table 49: Biomatrix III (LEADER Trial) 78
Data table 50: Biomatrix (STEALTH) 80
Data table 51: NEVO Sirolimus-eluting coronary stent (RES-ELUTION II) 81
Data table 52: NEVO Sirolimus-eluting coronary stent (RES-ELUTION I): Pivotal trial 83
Data table 53: GTX Coronary Stent System 84
Data table 54: ProGenic Pimecrolimus-eluting Coronary Stent System 85
Data table 55: MAHOROBA 87
Data table 56: ProLink LP 88
Data table 57: ChromoFlex Coronary Stent 89
Data table 58: ProNovember a Sirolimus Eluting Stent 90
Data table 59: Coroflex DEBlue (PEPCADIIIsub) 91
Data table 60: ENDEAVOR Resolute 92
Data table 61: TAXUS Petal Bifurcation Paclitaxel-Eluting Stent System 95
Data table 62: Coronary Stents : Pipeline Summary 97
Data table 63: Biosensors International Group Pipeline Products 104
Data table 64: Cook Medical Pipeline Products 105
Data table 65: OrbusNeich Pipeline Products 105
Data table 66: Vascular Concepts Limited Pipeline Products 106
Data table 67: CorNovember a, Inc Pipeline 107
Data table 68: Nexeon MedSystems, Inc Pipeline Products 107
Data table 69: Coronary Stents: Key Acquisitions 108

1.2 List of Charts
Chart 1: Signs and Symptoms of Coronary Heart Disease 10
Chart 2: Treatment Flow Model, Coronary Stents for Treatment of Coronary Heart Disease, US, 2009 12
Chart 3: Treatment Flow Model, Coronary Stents for Treatment of Coronary Heart Disease, Europe, 2009 13
Chart 4: Treatment Modalities for Coronary Heart Disease, 2009 15
Chart 5: Coronary Stents March ket, Global, Sales ($bn), 2002 - 2009 16
Chart 6: Coronary Stents March ket, Global, Sales ($bn), 2009 - 2016 17
Chart 7: Drivers and Restraints in the Coronary Stents March ket 18
Chart 8: US, Breakdown of Deaths from Cardiovascular Diseases, %,2006 18
Chart 9 Bare Metal Stents March ket, Global, Sales ($bn), 2002- 2009 22
Chart 10: Bare Metal Stents March ket, Global, Sales ($bn), 2009-2016 23
Chart 11: Drug Eluting Stents March ket, Global, Sales ($bn), 2002-2009 25
Chart 12: Drug Eluting Stents March ket, Global, Sales ($bn), 2009- 2016 26
Chart 13: Coronary Stents March ket, Cross Country Analysis, Global, Sales and growth Comparison from 2002 to 2016 28
Chart 14: Coronary Stents March ket, US, Sales ($ m), from 2002 to 2009 29
Chart 15: Coronary Stents March ket, US, Sales ($ m), from 2009 to 2016 30
Chart 16: Coronary Stents March ket, Canada, Sales ($ m), from 2002 to 2009 31
Chart 17: Coronary Stents March ket, Canada, Sales ($ m), from 2009 to 2016 32
Chart 18: Coronary Stents March ket, UK, Sales ($ m), from 2002 to 2009 33
Chart 19: Coronary Stents March ket, UK, Sales ($ m), from 2009 to 2016 34
Chart 20: Coronary Stents March ket, Italy, Sales ($ m), from 2002 to 2009 35
Chart 21: Coronary Stents March ket, Italy, Sales ($ m), from 2009 to 2016 36
Chart 22: Coronary Stents March ket, Germany, Sales ($ m), from 2002 to 2009 37
Chart 23: Coronary Stents March ket, Germany, Sales ($ m), from 2009 to 2016 38
Chart 24: Coronary Stents March ket, France, Sales ($ m), from 2002 to 2009 39
Chart 25: Coronary Stents March ket, France, Sales ($ m), from 2009 to 2016 40
Chart 26: Coronary Stents March ket, Spain, Sales ($ m), from 2002 to 2009 41
Chart 27: Coronary Stents March ket, Spain, Sales ($ m), from 2009 to 2016 42
Chart 28: Coronary Stents March ket, Japan, Sales ($ m), from 2002 to 2009 43
Chart 29: Coronary Stents March ket, Japan, Sales ($ m), from 2009 to 2016 44
Chart 30: Coronary Stents March ket,China, Sales ($ m), from 2002 to 2009 45
Chart 31: Coronary Stents March ket, China, Sales ($ m), from 2009 to 2016 46
Chart 32: Coronary Stents March ket, India, Sales ($ m), from 2002 to 2009 47
Chart 33: Coronary Stents March ket, India, Sales ($ m), from 2009 to 2016 48
Chart 34: Coronary Stents March ket, Brazil, Sales ($ m), from 2002 to 2009 49
Chart 35: Coronary Stents March ket, Brazil, Sales ($ m), from 2009 to 2016 50
Chart 36: Coronary Stents March ket, Australia, Sales ($ m), from 2002 to 2009 51
Chart 37: Coronary Stents March ket, Australia, Sales ($ m), from 2009 to 2016 52
Chart 38: Drug Eluting Stents March ket, Global, Market Shares (% of Sales ), 2009 53
Chart 39: Bare Metal Stents March ket, Global, Market Shares s (% Sales ), 2009 54
Chart 40: Pipeline Technology Assessment for Coronary Stents by Development Stage, World 74
Chart 41: Pipeline Technology Assessment for Drug Eluting and Bare Metal Stents By Development Stage, World 75
Chart 42: Pipeline Technology Assessment for Drug Eluting Stents by Unmet Need, World 76
Chart 43: Pipeline Technology Assessment for Bare Metal Stents by Unmet Need, World 77
Chart 44: Key Acquisitions in from 2009 to 2010 108
Chart 45: GlobalData Methodology 113

Companies mentioned
Boston Scientific Corporation
Cordis Corporation
Abbott Laboratories
Medtronic, Inc

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Aesculap: Organization, Technologies, Products, Marketing, R&D, Strategies

Aesculap: Organization, Technologies, Products, Marketing, R&D, Strategies

  • $ 1 850
  • Company report
  • July 2014
  • by Venture Planning Group

A strategic assessment of Aesculap, one of the world's leading orthopedics companies, provides significant competitor information, analysis, and insight critical to the development and implementation of ...

Biomet: Organization, Technologies, Products, Marketing, R&D, Strategies

Biomet: Organization, Technologies, Products, Marketing, R&D, Strategies

  • $ 1 850
  • Company report
  • July 2014
  • by Venture Planning Group

A strategic assessment of Biomet, one of the world's leading orthopedics companies, provides significant competitor information, analysis, and insight critical to the development and implementation of ...

ConMed: Organization, Facilities, Technologies, Products, Marketing, R&D, Strategies

ConMed: Organization, Facilities, Technologies, Products, Marketing, R&D, Strategies

  • $ 1 850
  • Company report
  • July 2014
  • by Venture Planning Group

A strategic assessment of ConMed, one of the world's leading orthopedics companies, provides significant competitor information, analysis, and insight critical to the development and implementation of ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.